Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction × zolbetuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 8 Adenocarcinoma 7 Neoplasms 6 Solid Tumors 2 Pancreatic Neoplasms 1 Metastatic Pancreatic Adenocarcinoma 1 Gastric Cancer Adenocarcinoma Metastatic 1 Esophageal Neoplasms 1 CLDN18.2-positive Gastric Adenocarcinoma 1 CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1 Adenocarcinoma Of Esophagus 1

Interventions

zolbetuximab 1 Oxaliplatin 1 Epirubicin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01630083 2025-06-15

FAST

Astellas Pharma Inc

Phase 2 Completed

Gastrointestinal

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡